Filing Flows › Ironwood Pharmaceuticals (IRWD) › R&D spending
Ironwood Pharmaceuticals (IRWD) R&D spending by quarter
Ironwood Pharmaceuticals' R&D spending was $28.4M in Q3 2026 (third quarter 2026), +26% from Q2 2026. Over the last 5 quarters it ranged from $21.9M (Q1 2026) to $28.4M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $28.4M | +26% | +26% |
| Q2 2026 | $22.4M | +2% | — |
| Q1 2026 | $21.9M | -2% | -20% |
| Q3 2025 | $22.5M | -18% | — |
| Q1 2025 | $27.4M | — | — |
Q3 2026 at a glance
Ironwood Pharmaceuticals, Q3 2026: revenue $133M (+9% year over year), operating margin 70.0%, net earnings $59.8M, operating cash flow $67.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ironwood Pharmaceuticals' R&D spending?
Ironwood Pharmaceuticals' R&D spending was $28.4M in Q3 2026 (third quarter 2026), +26% from Q2 2026.
How has Ironwood Pharmaceuticals' R&D spending changed?
Over the last 5 quarters it ranged from $21.9M (Q1 2026) to $28.4M (Q3 2026).
Q3 2026 results → · How Ironwood Pharmaceuticals makes money →